Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Response to Senate HELP Committee RFI on Diagnostics Regulation
-
ACMG Comments on FDA Proposed Rule for Regulation of LDTs
-
Stakeholder Letter Asking Congress Renew Efforts on CLIA Reform and Urge FDA to Halt LDT Rulemaking
-
Letter to FDA Requesting Extension of Comment Period for Proposed Rule on Regulation of LDTs
-
ACMG Request to FDA to Extend Comment Period for Proposed Rule on Regulation of LDTs
-
Sign-on Letter Concerning the Improving Care and Access to Nurses Act
-
Sign-on Letter Opposing Cigna Policy on Use of Modifier -25
-
ACMG Response to USPSTF Proposed Research Plan for Lynch Syndrome
-
Sign-on Letter Opposing Updated VALID Act & ACM Exemption
-
ACMG Letter Regarding Maryland Medicaid Policy for Carrier Screening